The Efficacy and Safety of B-Cell Maturation Antigen (BCMA) Antibody-Drug Conjugates (ADC) in Development against Cancer: A Systematic Review.

ABSTRACT:

Objectives

B-cell maturation antigen (BCMA)-targeted antibody-drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM.

Methods

A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I and SYRCLE's risk of bias tool.

Results

A total of 21 studies were included:

SUBMITTER: Shan J 

PROVIDER: S-EPMC12774553 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature